Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients

References

• Porcaro G, Bizzarri M, Monastra G, et al Strategies for the treatment of polycystic ovary syndrome (PCOS) women: the role of myo-inositol (MI) and d-chiro-inositol (DCI) between diet and therapy. In: Cobbs B, ed. Polycystic ovary syndrome (PCOS): clinical aspects, potential complications and dietary management. Hauppauge, NY: Nova science publishers; 2016, in press
   Google Scholar
• Nardo LG, Patchava S, Laing I. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications. Panminerva Med 2008;50:267–78
   PubMed Web of Science ®Google Scholar
• Orio F, Palomba S. Reproductive endocrinology: new guidelines for the diagnosis and treatment of PCOS. Nat Rev Endocrinol 2014;10:130–2
   PubMed Web of Science ®Google Scholar
• Orio F, Vuolo L, Palomba S, et al. Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol 2008;60:39–51
   PubMedGoogle Scholar
• Thomas MP, Mills SJ, Potter BV. The “other” inositols and their phosphates: synthesis, biology, and medicine (with recent advances in myo- inositol chemistry). Angew Chem Int Ed Engl 2015;54:2–39
   Google Scholar
• Hoglan FA, Bartow E. Inactive inositol and its derivatives. Ind Eng Chem 1939;31:749–50
   Google Scholar
• Takeo Y. Influence of continuous illumination on estrous cycle of rats: time course of changes in levels of gonadotropins and ovarian steroids until occurrence of persistent estrus. Neuroendocrinology 1984;39:97–104
   PubMed Web of Science ®Google Scholar
• Lowton IE, Schwartz NB. Pituitary-ovarian function in rats exposed to constant light: a chronological study. Endocrinology 1967;81:497–508
   PubMed Web of Science ®Google Scholar
• Jain P, Jain M, Haldar C, et al. Melatonin and its correlation with testosterone in polycystic ovarian syndrome. J Hum Reprod Sci 2013;6:253–8
   PubMedGoogle Scholar
• Tamura H, Nakamura Y, Korkmaz A, et al. Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril 2009;92:328–43
   PubMed Web of Science ®Google Scholar
• Anderson E, Lee GY. The polycystic ovarian (PCO) condition: apoptosis and epithelialization of the ovarian antral follicles are aspects of cystogenesis in the dehydroepiandrosterone (DHEA)-treated rat model. Tissue Cell 1997;29:171–89
   PubMed Web of Science ®Google Scholar
• Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome – a hypothesis. J Endocrinol 2002;174:1–5
   PubMed Web of Science ®Google Scholar
• Micić D, Zorić S, Popović V, et al. Androgen-producing bilateral large cortical adrenal adenomas associated with polycystic ovaries in a young female. Postgrad Med J 1992;68:219–22
   PubMed Web of Science ®Google Scholar
• Nelson VL, Legro RS, Strauss JF, III McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999;13:946–57
   PubMed Web of Science ®Google Scholar
• Liu YX, Hsueh AJ. Synergism between granulosa and theca-interstitial cells in estrogen biosynthesis by gonadotropin-treated rat ovaries: studies on the two-cell, two-gonadotropin hypothesis using steroid antisera. Biol Reprod 1986;35:27–36
   PubMed Web of Science ®Google Scholar
• Wide L, Naessén T, Sundström-Poromaa I, Eriksson K. Sulfonation and sialylation of gonadotropins in women during the menstrual cycle, after menopause, and with polycystic ovarian syndrome and in men. J Clin Endocrinol Metab 2007;92:4410–17
   PubMed Web of Science ®Google Scholar
• Hernández-Valencia M, Hernández-Quijano T, Sandoval A, et al. Changes in glycosylation of pituitary gonadotropins in polycystic ovary syndrome. Int J Reprod Fertil Sex Health 2014;1:20–4
   Google Scholar
• Ulloa-Aguirre A, Cravioto A, Damián-Matsumura P, et al. Biological characterization of the naturally occurring analogues of intrapituitary human follicle-stimulating hormone. Hum Reprod 1992;7:23–30
   PubMed Web of Science ®Google Scholar
• Zambrano E, Barrios-de-Tomasi J, Cárdenas M, Ulloa-Aguirre A. Studies on the relative in-vitro biological potency of the naturally-occurring isoforms of intrapituitary follicle stimulating hormone. Mol Hum Reprod 1996;2:563–71
   PubMedGoogle Scholar
• Timossi C, Barrios-de-Tomasi J, Zambrano E, Ulloa-Aguirre A. A naturally occurring basically charged human follicle-stimulating hormone (FSH) variant inhibits FSH-induced androgen aromatization and tissue-type plasminogen activator enzyme activity in vitro. Neuroendocrinology 1998;67:153–63
   PubMed Web of Science ®Google Scholar
• Salhanick AI, Amatruda JM. Role of sialic acid in insulin action and the insulin resistance of diabetes mellitus. Am J Physiol 1988;255:E173–9
   Google Scholar
• Loreti N, Ambao V, Andreone L, et al. Effect of sialylation and complexity of FSH oligosaccharides on inhibin production by granulosa cells. Reproduction 2013;145:127–35
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800
   PubMed Web of Science ®Google Scholar
• De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:633–67
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003;46:325–40
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;4:165–9
   Google Scholar
• Genazzani AD, Battaglia C, Malavasi B, et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004;81:114–19
   PubMed Web of Science ®Google Scholar
• Mayer SB, Evans WS, Nestler JE. Polycystic ovary syndrome and insulin: our understanding in the past, present and future. Womens Health (Lond) 2015;11:137–49
   PubMed Web of Science ®Google Scholar
• Selva DM, Hogeveen KN, Innis SM, Hammond GL. Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest 2007;117:3979–87
   PubMed Web of Science ®Google Scholar
• Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012;28:509–15
   PubMed Web of Science ®Google Scholar
• Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res 2001;56:295–308
   PubMedGoogle Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, et al. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol 2007;23:146–52
   PubMed Web of Science ®Google Scholar
• Stabile G, Borrielli I, Artenisio AC, et al. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2014;27:177–82
   PubMed Web of Science ®Google Scholar
• Orio F, Muscogiuri G, Palomba S. Could the Mediterranean diet be effective in women with polycystic ovary syndrome? A proof of concept. Eur J Clin Nutr 2015;69:974
   PubMed Web of Science ®Google Scholar
• Rocca ML, Venturella R, Mocciaro R, et al. Polycystic ovary syndrome: chemical pharmacotherapy. Expert Opin Pharmacother 2015;16:1369–93
   PubMed Web of Science ®Google Scholar
• De Leo V, Morgante G, Piomboni P, et al. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril 2007;88:113–17
   PubMed Web of Science ®Google Scholar
• Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004;89:2817–23
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Zullo F, Orio F Jr, Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;30:1–50
   PubMed Web of Science ®Google Scholar
• Romualdi D, Giuliani M, Cristello F, et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil Steril 2010;93:2303–10
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000;73:1149–54
   PubMed Web of Science ®Google Scholar
• Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled crossover trial. Hum Reprod 2007;22:2967–73
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity . Fertil Steril 2004;82:893–902
   PubMed Web of Science ®Google Scholar
• Cosma M, Swiglo BA, Flynn DN, et al. Clinical review: insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008;93:1135–42
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Jakubowicz DJ, et al. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:242–9
   PubMed Web of Science ®Google Scholar
• Sun TH, Heimark DB, Nguygen T, et al. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun 2002;293:1092–8
   PubMed Web of Science ®Google Scholar
• Nestler JE, Unfer V. Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecol Endocrinol 2015;31:501–5
   PubMed Web of Science ®Google Scholar
• Larner J. D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance . Int J Exp Diabetes Res 2002;3:47–60
   PubMedGoogle Scholar
• Ortmeyer HK. Dietary myoinositol results in lower urine glucose and in lower postprandial plasma glucose in obese insulin resistant rhesus monkeys. Obes Res 1996;4:569–75
   PubMedGoogle Scholar
• Janovick JA, Conn PM. Gonadotropin-releasing hormone (GnRH)-receptor coupling to inositol phosphate and prolactin production in GH3 cells stably transfected with rat GnRH receptor complementary deoxyribonucleic acid. Endocrinology 1994;135:2214–19
   PubMed Web of Science ®Google Scholar
• Goud PT, Goud AP, Van Oostveldt P, Dhont M. Presence and dynamic redistribution of type I inositol 1,4,5-trisphosphatereceptors in human oocytes and embryos during in-vitro maturation, fertilization and early cleavage divisions. Mol Hum Reprod 1999;5:441–51
   PubMed Web of Science ®Google Scholar
• Lowther KM, Weitzman VN, Maier D, Mehlmann LM. Maturation, fertilization, and the structure and function of the endoplasmic reticulum in cryopreserved mouse oocytes. Biol Reprod 2009;81:147–54
   PubMed Web of Science ®Google Scholar
• Chiu TT, Rogers MS, Briton-Jones C, Haines C. Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes . Hum Reprod 2003;18:408–16
   PubMed Web of Science ®Google Scholar
• Colazingari S, Fiorenza MT, Carlomagno G, et al. Improvement of mouse embryo quality by myo-inositol supplementation of IVF media. J Assist Reprod Genet 2014;31:463–9
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Nestler JE, Ostlund RE, et al. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod 2008;23:1439–46
   PubMed Web of Science ®Google Scholar
• Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med 2010;16:543–52
   PubMed Web of Science ®Google Scholar
• Romero G, Gámez G, Huang LC, et al. Anti-inositolglycan antibodies selectively block some of the actions of insulin in intact BC3H1 cells. Proc Natl Acad Sci USA 1990;87:1476–80
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord 2010;8:127–36
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8:417–23
   PubMedGoogle Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314–20
   PubMed Web of Science ®Google Scholar
• Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 2003;7:151–9
   PubMedGoogle Scholar
• Galazis N, Galazi M, Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecol Endocrinol 2011;27:256–62
   PubMed Web of Science ®Google Scholar
• Isabella R, Raffone E. Does ovary need D-chiro-inositol? J Ovarian Res 2012;5:14
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Di Cello A, et al. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertil Steril 2011;96:1128–33
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998;83:2001–5
   PubMed Web of Science ®Google Scholar
• Unfer V, Carlomagno G, Papaleo E, et al. Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci 2014;21:854–8
   PubMed Web of Science ®Google Scholar
• Asplin I, Galasko G, Larner J. Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myoinositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA 1993;90:5924–8
   PubMed Web of Science ®Google Scholar
• Rice S, Christoforidis N, Gadd C, et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod 2005;20:373–81
   PubMed Web of Science ®Google Scholar
• Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril 2011;95:2515–16
   PubMed Web of Science ®Google Scholar
• Heimark D, McAllister J, Larner J. Decreased myo-inositol to chiro-inositol (m/c) ratios and increased m/c epimerase activity in pcos theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J 2013;61:111–17
   PubMed Web of Science ®Google Scholar
• Chiu TT, Rogers MS, Law EL, et al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002;17:1591–6
   PubMed Web of Science ®Google Scholar
• Shears SB, Ganapathi SB, Gokhale NA, et al. Defining signal transduction by inositol phosphates. Subcell Biochem 2012;59:389–412
   PubMedGoogle Scholar
• Michell RH. Inositol derivatives: evolution and functions. Nat Rev Mol Cell Biol 2008;9:151–61
   PubMed Web of Science ®Google Scholar
• Holub BJ. Metabolism and function of myo-inositol and inositol phospholipids. Annu Rev Nutr 1986;6:563–97
   PubMed Web of Science ®Google Scholar
• Lahiri A, Majumder, Biswas BB, eds. Biology of inositols and phosphoinositides. subcellular biochemistry Vol. 39. Berlin: Springer; 2006
   Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139–44
   PubMed Web of Science ®Google Scholar
• Dinicola S, Chiu TTY, Unfer V, Carlomagno G, Bizzarri M. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol 2014;54:1079–92
   PubMed Web of Science ®Google Scholar
• Morgante G, Orvieto R, Di Sabatino A, et al. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertil Steril 2011;95:2642–4
   PubMed Web of Science ®Google Scholar
• Kamenov Z, Kolarov G, Gateva A, et al. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol 2015;31:131–5
   PubMed Web of Science ®Google Scholar
• Lisi F, Carfagna P, Oliva MM, et al. Pretreatment with myo-inositol in non-polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol 2012;23:52
   Web of Science ®Google Scholar
• Minozzi M, Costantino D, Guaraldi C, Unfer V. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol 2011;27:920–4
   PubMed Web of Science ®Google Scholar
• Zacchè MM, Caputo L, Filippis S, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:508–13
   PubMed Web of Science ®Google Scholar
• For a review see: Bizzarri M, Cucina A, Harrath AH, et al. Does myo-inositol effect on PCOS follicles involve cytoskeleton regulation? Med Hypotheses 2016;91:1–5
   PubMed Web of Science ®Google Scholar
• Nestler JE. Modulation of aromatase and P450 cholesterol side-chain cleavage enzyme activities of human placental cytotrophoblasts by insulin and insulin-like growth factor I. Endocrinology 1987;121:1845–52
   PubMed Web of Science ®Google Scholar
• Nestler JE. Insulin and insulin-like growth factor-I stimulate the 3 beta-hydroxysteroid dehydrogenase activity of human placental cytotrophoblasts. Endocrinology 1989;125:2127–33
   PubMed Web of Science ®Google Scholar
• Vucenik I, Ramakrishna G, Tantivejkul K, et al. Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation. Breast Cancer Res Treat 2005;91:35–45
   PubMed Web of Science ®Google Scholar
• Ortega HH, Salvetti NR, Müller LA, et al. Characterization of cytoskeletal proteins in follicular structures of cows with cystic ovarian disease. J Comp Pathol 2007;136:222–30
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Dante G, Neri I. The ratio of MI to DCI and its impact in the treatment of polycystic ovary syndrome: experimental and literature evidences. Front Gynecol Endocrinol 2015;3:103–9
   Google Scholar
• Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trialArch. Arch Gynecol Obstet 2013;288:1405–11
   PubMed Web of Science ®Google Scholar
• Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012;16:575–81
   PubMed Web of Science ®Google Scholar
• Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol 2010;26:275–80
   PubMed Web of Science ®Google Scholar
• Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004;10:107–17
   PubMed Web of Science ®Google Scholar
• Głuszak O, Stopińska-Głuszak U, Glinicki P, et al. Phenotype and Metabolic Disorders in Polycystic Ovary Syndrome, ISRN Endocrinol 2012;2012:569862. doi:10.5402/2012/569862, modified
   PubMedGoogle Scholar